Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LymphoEnergy: Deferiprone Ex Vivo in Parkinson's and ALS
NCT02880033Completed
- Sponsor
- CHU de Lille
- Start
- Feb 2011
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of deferiprone in Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by CHU de Lille. Primary endpoint: Hydroxyl radical level at 12 months. Started Feb 2011; status: completed.
02
Drugs
deferiprone
03
Conditions
Parkinson's disease (PD)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02880033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02880033.